Nav: Home

AI-guided robotics enable automation of complex synthetic biological molecules

September 17, 2019

CAMBRIDGE, Mass., September 17, 2019 - A cross-disciplinary team of MIT researchers have published details of an artificial intelligence (AI) guided robotic platform for flow synthesis of small molecule organic compounds. The paper appeared in the August 9, 2019 issue of Science.

While small organic molecules are essential for many disciplines including drug discovery, the identification and development of synthetic routes creates a bottleneck due to the need for time-consuming manual tasks and lengthy design-synthesize-test iterations. Despite the availability of laboratory automation, experimental synthesis platforms still require manual configuration by expert chemists.

In this publication, the authors describe the development and use of a platform that combines artificial intelligence-driven synthesis planning, flow chemistry and a robotically controlled experimental platform to minimize the need for human intervention in the synthesis process from ideation through to manufacturing. Synthetic routes are proposed through generalization of millions of published chemical reactions and validated in silico to maximize the likelihood of success. Additional implementation details are determined by expert chemists and recorded in recipe files, which are executed by a modular continuous-flow platform that is automatically reconfigured by a robotic arm to set up the required unit operations and carry out the reaction.

"One of the major challenges in automating small molecule synthesis is the diversity of organic reactions and the difficulty in finding compatible reaction conditions to support multistep synthesis. Additionally, creating a system capable of supporting the range of reaction conditions in terms of temperatures, pressures and chemical compatibilities poses a serious engineering challenge," said Justin Lummiss, PhD, a co-first author on the Science publication who conducted research as a Postdoctoral Fellow at MIT.

Lummiss and Dale Thomas, PhD (another co-first author of the Science paper) are leveraging an AI-guided approach to address similar, longstanding challenges with custom peptide synthesis and purification at Mytide Therapeutics. Mytide is using AI to enable end-to-end peptide manufacturing in a truly autonomous fashion, including optimized reaction planning, real-time process optimization for in-sequence process modifications and robotics.

"Similar challenges exist in the automation of small molecule and peptide synthesis," noted Dr. Lummiss, who is now a Senior Scientist at Mytide. "We have made important strides in addressing significant engineering obstacles for small molecules and are now focused on new challenges with peptide synthesis and manufacturing".

Thomas and Lummiss' current work at Mytide Therapeutics focuses on the development of an integrated platform for peptide manufacturing and discovery of novel peptide therapeutics. The AI-guided, automated platform is designed to address challenges not only in synthesis but also in purification of custom peptides.

"The fully automated platform we are developing at Mytide simplifies the challenges of peptide synthesis through mastery of a single reaction - amide bond formation," noted Dr. Thomas, a Co-Founder of Mytide. "By reducing the synthetic diversity of conventional approaches to peptide synthesis, we have been able to address longstanding challenges in synthesis and purification, as well as reducing barriers of purity bottlenecks that presently limit current large-scale peptide manufacturing for drug products".

Thomas and Lummiss are excited about the future applications of their current work at Mytide and its ability to have a meaningful impact. Their advances in AI-guided automation and technology are driving Mytide's ultimate goal of accelerating the discovery and development of peptide therapeutics targeting a wide range of diseases, including cancer therapy, infectious disease, and inflammatory disorders.
About Mytide Therapeutics

Mytide Therapeutics' multi-disciplinary team of engineers, biochemists and computer scientists has created the first company to take a technologically advanced approach to solving long-standing challenges in both peptide synthesis and purification. Mytide's fully automated peptide manufacturing technology, coupled with predictive analytics and machine learning, is challenging decades-old paradigms to enable cost-efficient research and development, therapeutic manufacturing and therapeutic discovery. Our aim is to accelerate the discovery and development of life-saving peptide therapeutics for serious conditions ranging from metabolic conditions to oncology to inflammatory disorders to infectious diseases.

The Yates Network

Related Synthesis Articles:

Ammonia synthesis made easy with 2D catalyst
Rice University researchers use their knowledge of 2D nanomaterials and develop a 'green' method for the small-scale synthesis of ammonia.
New synthesis method yields degradable polymers
MIT chemists have come up with a way to make certain drug-delivery polymers more readily degradable by adding a novel type of building block to the polymer backbone.
A new strategy for the synthesis of complex natural products
Chemists from the University of Basel have succeeded in synthesizing two complex natural products from the group of dithiodiketopiperazines (DTPs).
A new, unified pathway for prebiotic RNA synthesis
Adding to support for the RNA world hypothesis, Sidney Becker and colleagues have presented what's not been shown before -- a single chemical pathway that could generate both the purine and pyrimidine nucleosides, the key building blocks of RNA.
Bottom-up synthesis of crystalline 2D polymers
Scientists at TU Dresden and Ulm University have succeeded in synthesizing sheet-like 2D polymers by a bottom-up process for the first time.
Clarification of a new synthesis mechanism of semiconductor atomic sheet
Researchers at Tohoku University in Japan succeeded in clarifying a new synthesis mechanism regarding transition metal dichalcogenides (TMD), which are semiconductor atomic sheets having thickness in atomic order.
Synthesis of UV absorbers from cashew nut shell liquid
Researchers succeeded in using cashew nut shell liquid (CNSL) as a substitute for petroleum in organic synthesis.
Can't get thinner than this: synthesis of atomically flat boron sheets
Scientists at Tokyo Institute of Technology (Tokyo Tech) find a simple method for producing atomically thin layers of oxidized borophene, a promising 2D boron-based nanomaterial that could serve in a variety of fields.
New synthesis method opens up possibilities for organic electronics
Scientists at Tokyo Institute of Technology (Tokyo Tech) modify a previous synthesis method to create a new semiconducting polymer with remarkable properties which could be used in organic electronic devices such as thin film transistors.
Small-volume, high-throughput organic synthesis
University of Groningen Professor of Drug Design, Alexander Dömling, has devised a method to rapidly synthesize thousands of new molecules and evaluate their properties as potential drugs.
More Synthesis News and Synthesis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at